In recent years, we have seen pharmaceutical company megadeals that saw Takeda acquiring Shire for a total value of $81.7 billion, Bristol-Myers Squibb’s acquisition of Celgene for $74 billion, AbbVie’s $63 billion acquisition of Allergan and the proposed acquisition of Alexion by AstraZeneca for $39 billion. All of these acquisitions continue to have a lasting impact on the leadership and staff at these companies, which collectively employ hundreds of thousands of employees worldwide. In addition, there have been a plethora of product transfers between organisations with larger multi-national companies pruning portfolios, adding gene therapy and biotechnology divisions, and consolidating core assets. John Cahill at PharmaLex shows how mergers and acquisitions in the pharmaceutical/biopharmaceutical industry
are critical for organisations to implement strategic changes to their business.